DE69526344T2 - Stabilgelzusammensetzung zur topischen behandlung von hautkrankheiten - Google Patents

Stabilgelzusammensetzung zur topischen behandlung von hautkrankheiten

Info

Publication number
DE69526344T2
DE69526344T2 DE69526344T DE69526344T DE69526344T2 DE 69526344 T2 DE69526344 T2 DE 69526344T2 DE 69526344 T DE69526344 T DE 69526344T DE 69526344 T DE69526344 T DE 69526344T DE 69526344 T2 DE69526344 T2 DE 69526344T2
Authority
DE
Germany
Prior art keywords
gel
topical treatment
active agent
skin diseases
stabilized composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69526344T
Other languages
English (en)
Other versions
DE69526344D1 (de
Inventor
Prakash M Charu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of DE69526344D1 publication Critical patent/DE69526344D1/de
Application granted granted Critical
Publication of DE69526344T2 publication Critical patent/DE69526344T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/042—Gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/67—Vitamins
    • A61K8/671—Vitamin A; Derivatives thereof, e.g. ester of vitamin A acid, ester of retinol, retinol, retinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
DE69526344T 1994-06-07 1995-06-07 Stabilgelzusammensetzung zur topischen behandlung von hautkrankheiten Expired - Lifetime DE69526344T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25509494A 1994-06-07 1994-06-07
PCT/US1995/007338 WO1995033489A1 (en) 1994-06-07 1995-06-07 Stable gel formulation for topical treatment of skin conditions

Publications (2)

Publication Number Publication Date
DE69526344D1 DE69526344D1 (de) 2002-05-16
DE69526344T2 true DE69526344T2 (de) 2002-11-07

Family

ID=22966815

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69535184T Expired - Lifetime DE69535184T2 (de) 1994-06-07 1995-06-07 Stabile Gelzusammensetzung zur topischen Behandlung von Hautkrankheiten
DE69526344T Expired - Lifetime DE69526344T2 (de) 1994-06-07 1995-06-07 Stabilgelzusammensetzung zur topischen behandlung von hautkrankheiten

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE69535184T Expired - Lifetime DE69535184T2 (de) 1994-06-07 1995-06-07 Stabile Gelzusammensetzung zur topischen Behandlung von Hautkrankheiten

Country Status (13)

Country Link
US (2) US5914334A (de)
EP (2) EP1147778B1 (de)
AT (2) ATE215836T1 (de)
AU (1) AU693905B2 (de)
CA (1) CA2191773C (de)
DE (2) DE69535184T2 (de)
DK (1) DK1147778T3 (de)
ES (2) ES2269296T3 (de)
IL (3) IL122359A (de)
PT (1) PT1147778E (de)
TW (1) TW379143B (de)
WO (1) WO1995033489A1 (de)
ZA (1) ZA954599B (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
IT1288708B1 (it) * 1996-10-17 1998-09-23 Achille Sandoli Composizione farmaceutica comprendente trometamina per il trattamento per via topica dell'acne vulgaris.
WO1998036753A1 (en) * 1997-02-20 1998-08-27 Allergan Sales,Inc. Tazarotene and corticosteroid treatment for psoriasis
CA2293303A1 (en) * 1997-06-11 1998-12-17 Allergan Sales, Inc. Tazarotene and uvb phototherapy treatment for psoriasis
JP2002512638A (ja) * 1998-03-30 2002-04-23 ザ、プロクター、エンド、ギャンブル、カンパニー スキンケア組成物
US20020160995A1 (en) * 1998-08-03 2002-10-31 Easterling W. Jerry Medication and method for remediating existing scars through transdermal, topical delivery of calcium channel blockers
US20090098065A1 (en) * 2000-01-11 2009-04-16 Avikam Harel Composition and methods for the treatment of skin disorders
US7179483B2 (en) * 2000-04-26 2007-02-20 Watson Pharmaceuticals, Inc. Compositions and methods for transdermal oxybutynin therapy
ATE488233T1 (de) * 2000-04-26 2010-12-15 Watson Pharmaceuticals Inc Verminderung der nebenwirkungen bei der oxybutynin-therapie
US7029694B2 (en) 2000-04-26 2006-04-18 Watson Laboratories, Inc. Compositions and methods for transdermal oxybutynin therapy
FR2830449B1 (fr) * 2001-10-05 2004-04-23 Fabre Pierre Dermo Cosmetique Utilisation du tazarotene pour la preparation d'un vernis a ongles pour le traitement et/ou la prevention du psoriasis et un vernis a ongles le contenant
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
DK2020243T3 (en) * 2002-05-28 2018-11-19 Astrazeneca Ab Pharmaceutical composition which can be applied topically
US20040018220A1 (en) * 2002-07-26 2004-01-29 Chiou Consulting, Inc. Aqueous compositions for facial cosmetics
FR2848451B1 (fr) * 2002-12-17 2007-01-12 Galderma Res & Dev Procede de stabilisation chimique d'un retinoide solubilise et composition aqueuse obtenue selon le procede comprenant au moins un retinoide sous forme salifiee
JP2006511547A (ja) * 2002-12-17 2006-04-06 ガルデルマ・リサーチ・アンド・デヴェロップメント・エス・エヌ・セ 塩基を使用する、溶媒中における可溶化レチノイドの化学的安定化方法
AU2006245283B2 (en) 2005-05-10 2012-11-01 Dermipsor Ltd. Compositions and methods for treating hyperproliferative epidermal diseases
AR054805A1 (es) * 2005-06-29 2007-07-18 Stiefel Laboratories Composiciones topicas para el tratamiento de la piel
US20070060620A1 (en) * 2005-09-09 2007-03-15 John Sefton Use of RAR retinoid agonists to increase sperm count and sperm mobility in males
US20070077220A1 (en) * 2005-09-30 2007-04-05 Ramirez Jose E Stable ascorbic acid compositions
US20070178058A1 (en) * 2006-02-02 2007-08-02 Ramirez Jose E Methods of using stable ascorbic acid compositions
US20070269534A1 (en) * 2006-02-02 2007-11-22 Ramirez Jose E Methods of treating skin to enhance therapeutic treatment thereof
US9107844B2 (en) * 2006-02-03 2015-08-18 Stiefel Laboratories Inc. Topical skin treating compositions
MX2008012526A (es) 2006-03-31 2008-10-14 Stiefel Res Australia Pyt Ltd Gel espumoso en suspension.
MXPA06008988A (es) * 2006-08-08 2008-02-07 Fernando Ahumada Ayala Preparaciones topicas antiacne que contienen retinoide (tazaroteno o adapaleno), antibiotico (fosfato de clindamicina) y/o queratolitico (peroxido de bonzoilo en microesponjas).
WO2008106646A2 (en) * 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
US9107815B2 (en) 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
US20110117182A1 (en) * 2009-07-30 2011-05-19 Allergan, Inc. Combination of dapsone with other anti-acne agents
ES2626151T3 (es) 2010-03-12 2017-07-24 Monsanto Technology Llc Composiciones agroquímicas en gel
JP2013538868A (ja) * 2010-10-08 2013-10-17 ヘルパービー セラピューティクス リミテッド 新規な組成物
EP3065702B1 (de) 2013-10-31 2023-06-07 Sun Pharmaceutical Industries Ltd Topische pharmazeutische zusammensetzung von acitretin
JP2022506944A (ja) * 2018-11-08 2022-01-17 ヴァーソナ セラピューティクス，インコーポレーテッド ５－α－レダクターゼ阻害剤の局所製剤及びそれらの使用
US11311556B2 (en) 2020-05-13 2022-04-26 Varsona Therapeutics, Inc. Topical dutasteride emulsions for treating endocrine therapy-induced alopecia
KR20230039979A (ko) * 2021-09-15 2023-03-22 서울대학교산학협력단 아토피 피부염 예방 또는 치료용 겔 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3934028A (en) * 1974-04-22 1976-01-20 The Regents Of The University Of California Acne and psoriasis treatment with retinoic acid analogs
US4895727A (en) * 1985-05-03 1990-01-23 Chemex Pharmaceuticals, Inc. Pharmaceutical vehicles for exhancing penetration and retention in the skin
US4810804A (en) * 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
CA2063576C (en) * 1989-06-07 1994-01-25 Gail S. Bazzano Slow release vehicles for minimizing skin irritancy of topical compositions
AU670777B2 (en) * 1992-04-16 1996-08-01 Ortho Pharmaceutical Corporation Aqueous gel vehicles for retinoids
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
CA2293303A1 (en) * 1997-06-11 1998-12-17 Allergan Sales, Inc. Tazarotene and uvb phototherapy treatment for psoriasis
US6017938A (en) * 1998-07-28 2000-01-25 Bershad; Susan Short contact treatment for acne
US6114348A (en) * 1999-03-10 2000-09-05 Weber; Paul J. Method of treating warts using tazarotene

Also Published As

Publication number Publication date
ES2269296T3 (es) 2007-04-01
US6258830B1 (en) 2001-07-10
DE69526344D1 (de) 2002-05-16
EP1147778A1 (de) 2001-10-24
EP0764032A1 (de) 1997-03-26
ATE336263T1 (de) 2006-09-15
AU2821895A (en) 1996-01-04
PT1147778E (pt) 2006-12-29
TW379143B (en) 2000-01-11
ES2173958T3 (es) 2002-11-01
IL114049A0 (en) 1995-10-31
AU693905B2 (en) 1998-07-09
ATE215836T1 (de) 2002-04-15
EP1147778B1 (de) 2006-08-16
CA2191773C (en) 2004-08-10
ZA954599B (en) 1996-01-26
IL122358A (en) 2001-01-28
DE69535184T2 (de) 2007-08-23
DE69535184D1 (de) 2006-09-28
CA2191773A1 (en) 1995-12-14
US5914334A (en) 1999-06-22
IL122359A (en) 2001-08-26
WO1995033489A1 (en) 1995-12-14
DK1147778T3 (da) 2006-12-18
IL114049A (en) 2000-08-31
EP0764032B1 (de) 2002-04-10

Similar Documents

Publication Publication Date Title
DE69526344D1 (de) Stabilgelzusammensetzung zur topischen behandlung von hautkrankheiten
ATE214933T1 (de) Dermatologische zusammensetzungen, welche benzylneroxid und ein mittel zur verminderung von hautreizungen enthalten
FR2782269B1 (fr) Composition cosmetique et/ou dermatologique contenant de l'acide salicylique ou un derive d'acide salicylique et son utilisation
PT772600E (pt) Compostos de imidazolilo substituido nas posicoes 1 e 2 para o tratamento da inflamacao
DE69311257T2 (de) Methoxyiminoessigsäure-Derivate und Fungizide für Landwirtschaft und Gartenbau, die diese als aktive Bestandteile enthalten
CA2291144A1 (en) Topical treatment of psoriasis using neutralizing antibodies to il-8
ATE245452T1 (de) Hyaluronatlyase als penetrationsförderer in topischen mitteln
ATE249819T1 (de) Präparate zur äusserlichen anwendung zur behandlung von dermatosen
DE69932939D1 (de) Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
DE69315927T2 (de) Kosmetische Zusammensetzung, die einen Lipidstoff und eine Hydroxy - oder Ketofettsäure enthält
ATE160561T1 (de) L-carnitin-salz, dieses enthaltende kosmetische und pharmazeutische zusammensetzungen zur behandlung von dermatosen
NZ506681A (en) Disinfecting composition
CA2322878A1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
DE69919597D1 (de) Topische formulierungen, die hautpenetrations-mittel enthalten, und ihre verwendung
NO941097L (no) Hudregenererende kosmetisk preparat
ATE168004T1 (de) Juckreizstillendes mittel
ATE86611T1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
DE69825322D1 (de) Topische carbamazepin-formulierungen und deren verwendung
RU97107046A (ru) Мазь "аникол" для лечения ран, воспалительных и кожных заболеваний у животных
RU96108909A (ru) Ибупрофен и флурбипрофен как противозудное средство
HUP9902703A2 (hu) Száraz peszticid készítmények állatokon előforduló ektoparaziták írtására
TH43881A (th) ส่วนประกอบใช้เฉพาะที่สำหรับการควบคุมลักษณะแสดงออกของผิวหนังที่มันเป็นเงา